Skip to main navigation Skip to search Skip to main content

Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity

  • Yingjie Yu
  • , Aiyao Liu
  • , Gagan Dhawan
  • , Haibo Mei
  • , Wei Zhang
  • , Kunisuke Izawa
  • , Vadim A. Soloshonok
  • , Jianlin Han
  • Nanjing Forestry University
  • University of Delhi
  • Hamari Chemicals, Ltd.
  • University of the Basque Country
  • Ikerbasque Basque Foundation for Science

Research output: Contribution to journal › Review article › peer-review

Abstract

Thirteen new fluorine-containing drugs, which have been granted approval by the US Food and Drug Administration (FDA) in 2020, are profiled in this review. Therapeutic areas of these new fluorinated pharmaceuticals include medicines and diagnostic agents for Cushing's disease, neurofibromatosis, migraine, Alzheimer's disease, myelodysplastic syndromes, hereditary angioedema attacks, and various cancers. Molecules of these approved drugs feature aromatic fluorine (Ar-F) (11 compounds), aromatic Ar-CF3 (1), aliphatic CHF (1) and CF2 (1) groups. For each compound, we provide a spectrum of biological activity, medicinal chemistry discovery, and synthetic approaches.

Original languageEnglish
Pages (from-to)3342-3354
Number of pages13
JournalChinese Chemical Letters
Volume32
Issue number11
DOIs
StatePublished - Nov 2021

ASJC Scopus Subject Areas

  • General Chemistry

Keywords

  • Asymmetric synthesis
  • Blockbuster drugs
  • Drug design and development
  • Fluorine and compounds
  • Modern pharmaceuticals
  • Synthesis

Fingerprint

Dive into the research topics of 'Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity'. Together they form a unique fingerprint.

Cite this